Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Korea Ltd. ) Identifier:
First received: July 17, 2009
Last updated: September 27, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2009
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)